Cargando…

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Bedaquiline is recommended for the treatment of all patients with rifampin-resistant tuberculosis (RR-TB). Bedaquiline accumulates within cells, but its intracellular pharmacokinetics have not been characterized, which may have implications for dose optimization. We developed a novel assay using hig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngwalero, Precious, Brust, James C. M., van Beek, Stijn W., Wasserman, Sean, Maartens, Gary, Meintjes, Graeme, Joubert, Anton, Norman, Jennifer, Castel, Sandra, Gandhi, Neel R., Denti, Paolo, McIlleron, Helen, Svensson, Elin M., Wiesner, Lubbe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522761/ https://www.ncbi.nlm.nih.gov/pubmed/34370588 http://dx.doi.org/10.1128/AAC.02399-20

Ejemplares similares

Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment
por: van Beek, Stijn W, et al.
Publicado: (2022)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

Clofazimine pharmacokinetics in patients with TB: dosing implications
por: Abdelwahab, Mahmoud Tareq, et al.
Publicado: (2020)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis
por: Abdelgawad, Noha, et al.
Publicado: (2022)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2021)

Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis
por: Mazanhanga, Marian, et al.
Publicado: (2023)

Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study
por: Brust, James C M, et al.
Publicado: (2021)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay
por: Joubert, Andre, et al.
Publicado: (2022)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
por: Svensson, Elin M., et al.
Publicado: (2017)

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
por: Svensson, Elin M., et al.
Publicado: (2018)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
por: Rockwood, Neesha, et al.
Publicado: (2017)

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
por: Denti, Paolo, et al.
Publicado: (2015)

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review
por: Lawn, Stephen D, et al.
Publicado: (2013)

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children
por: Bienczak, Andrzej, et al.
Publicado: (2017)

“Weighting” the Evidence: How Much Bedaquiline Is Enough?
por: Brust, James C. M.
Publicado: (2023)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis
por: Schaaf, Hendrik Simon, et al.
Publicado: (2009)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
por: van der Laan, Louvina E., et al.
Publicado: (2021)

Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis
por: Court, R. G., et al.
Publicado: (2018)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
por: Griesel, Rulan, et al.
Publicado: (2023)

Clofazimine for the treatment of tuberculosis
por: Stadler, Jacob A. M., et al.
Publicado: (2023)

Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors
por: Pepper, Dominique J, et al.
Publicado: (2010)

Population pharmacokinetics of ethambutol in African children: a pooled analysis
por: Tikiso, Tjokosela, et al.
Publicado: (2022)

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Modelling of mycobacterial load reveals bedaquiline’s exposure–response relationship in patients with drug-resistant TB
por: Svensson, Elin M, et al.
Publicado: (2017)

The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy
por: Decloedt, Eric H., et al.
Publicado: (2012)

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
por: Shiau, Stephanie, et al.
Publicado: (2014)

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
por: Francis, Jose, et al.
Publicado: (2019)

Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial
por: Wallis, Robert S., et al.
Publicado: (2018)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
por: Svensson, Elin M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q0bpjkf2nm9o2guqgle5ifldkm